Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

23 października 2017 zaktualizowane przez: Radiation Therapy Oncology Group

A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer

RATIONALE: Zoledronate may prevent bone loss in patients with prostate cancer undergoing radiation therapy and hormone therapy. It is not yet known whether zoledronate is more effective than calcium and vitamin D alone in preventing osteoporosis and bone fractures in patients with prostate cancer.

PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to calcium and vitamin D alone in preventing osteoporosis and bone fractures in patients with locally advanced nonmetastatic prostate cancer undergoing radiation therapy and hormone therapy.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

OBJECTIVES:

Primary

  • Compare the potential benefit of bisphosphonate therapy comprising zoledronate plus vitamin D and calcium supplement vs standard therapy with vitamin D and calcium supplement in the prevention of osteoporosis and associated bone fractures in patients with locally advanced nonmetastatic adenocarcinoma of the prostate undergoing radiotherapy and luteinizing hormone-releasing hormone (LHRH) agonist therapy.

Secondary

  • Evaluate the potential benefit of these regimens on quality of life in these patients.
  • Evaluate the potential benefit in bone mineral density over a period of 3 years for patients treated with these regimens.

OUTLINE: This is randomized multicenter study. Patients are stratified according to T score of the hip by dual x-ray absorptiometry (DXA) scan (< -1.0 but > -2.5 vs ≥ - 1.0) and planned duration of luteinizing hormone-releasing hormone (LHRH) agonist therapy (1-2½ years vs > 2½ years). Patients are randomized to 1 of 2 treatment arms.

Quality of life is assessed at baseline and every 6 months during treatment.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

109

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Kanada
    • British Columbia
      • Victoria, British Columbia, Kanada, V8R 6V5
        • British Columbia Cancer Agency - Vancouver Island Centre
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
        • Doctor H. Bliss Murphy Cancer Centre
    • Ontario
      • Hamilton, Ontario, Kanada, L8V 5C2
        • Margaret and Charles Juravinski Cancer Centre
      • Thunder Bay, Ontario, Kanada, P7B 6V4
        • Cancer Care Program at Thunder Bay Regional Health Sciences
    • Quebec
      • Montreal, Quebec, Kanada, H1T 2M4
        • Maisonneuve-Rosemont Hospital
      • Quebec City, Quebec, Kanada, G1R 2J6
        • Centre Hospitalier Universitaire de Quebec
      • Sherbrooke, Quebec, Kanada, J1H 5N4
        • CHUS-Hopital Fleurimont
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4T 7T1
        • Allan Blair Cancer Centre at Pasqua Hospital
  • Stany Zjednoczone
    • California
      • Chico, California, Stany Zjednoczone, 95926
        • Enloe Cancer Center at Enloe Medical Center
      • Los Angeles, California, Stany Zjednoczone, 90089-9181
        • USC/Norris Comprehensive Cancer Center and Hospital
      • Pomona, California, Stany Zjednoczone, 91767
        • Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
      • Roseville, California, Stany Zjednoczone, 95661
        • Radiation Oncology Center - Roseville
      • Sacramento, California, Stany Zjednoczone, 95815
        • Radiological Associates of Sacramento Medical Group, Incorporated
    • Colorado
      • Colorado Springs, Colorado, Stany Zjednoczone, 80933
        • Penrose Cancer Center at Penrose Hospital
      • Pueblo, Colorado, Stany Zjednoczone, 81004
        • St. Mary - Corwin Regional Medical Center
    • Georgia
      • Gainesville, Georgia, Stany Zjednoczone, 30501
        • Northeast Georgia Medical Center
    • Illinois
      • Alton, Illinois, Stany Zjednoczone, 62002
        • Saint Anthony's Hospital at Saint Anthony's Health Center
      • Arlington Heights, Illinois, Stany Zjednoczone, 60005
        • Northwest Community Hospital
      • Harvey, Illinois, Stany Zjednoczone, 60426
        • Ingalls Cancer Care Center at Ingalls Memorial Hospital
      • Olympia Fields, Illinois, Stany Zjednoczone, 60461
        • Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
      • Urbana, Illinois, Stany Zjednoczone, 61801
        • CCOP - Carle Cancer Center
    • Indiana
      • Goshen, Indiana, Stany Zjednoczone, 46526
        • Center for Cancer Care at Goshen General Hospital
      • Indianapolis, Indiana, Stany Zjednoczone, 46202
        • Methodist Cancer Center at Methodist Hospital
    • Kentucky
      • Lexington, Kentucky, Stany Zjednoczone, 40536-0093
        • Lucille P. Markey Cancer Center at University of Kentucky
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21231-2410
        • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      • Baltimore, Maryland, Stany Zjednoczone, 21229
        • St. Agnes Hospital Cancer Center
    • Michigan
      • Detroit, Michigan, Stany Zjednoczone, 48202
        • Josephine Ford Cancer Center at Henry Ford Hospital
      • Detroit, Michigan, Stany Zjednoczone, 48201-1379
        • Barbara Ann Karmanos Cancer Institute
      • Kalamazoo, Michigan, Stany Zjednoczone, 49007-3731
        • West Michigan Cancer Center
    • Minnesota
      • Saint Cloud, Minnesota, Stany Zjednoczone, 56303
        • CentraCare Clinic - River Campus
      • Saint Cloud, Minnesota, Stany Zjednoczone, 56303
        • Coborn Cancer Center
    • Missouri
      • Cape Girardeau, Missouri, Stany Zjednoczone, 63701
        • Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
      • Kansas City, Missouri, Stany Zjednoczone, 64131
        • CCOP - Kansas City
      • Saint Louis, Missouri, Stany Zjednoczone, 63141
        • CCOP - St. Louis-Cape Girardeau
      • Saint Louis, Missouri, Stany Zjednoczone, 63110
        • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
      • Saint Louis, Missouri, Stany Zjednoczone, 63141
        • David C. Pratt Cancer Center at St. John's Mercy
      • Springfield, Missouri, Stany Zjednoczone, 65804
        • St. John's Regional Health Center
      • Springfield, Missouri, Stany Zjednoczone, 65807
        • Hulston Cancer Center at Cox Medical Center South
    • Montana
      • Billings, Montana, Stany Zjednoczone, 59101
        • CCOP - Montana Cancer Consortium
      • Billings, Montana, Stany Zjednoczone, 59101
        • Northern Rockies Radiation Oncology Center
      • Great Falls, Montana, Stany Zjednoczone, 59405
        • Great Falls Clinic - Main Facility
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89102
        • University Medical Center of Southern Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89106
        • CCOP - Nevada Cancer Research Foundation
      • Reno, Nevada, Stany Zjednoczone, 89502
        • Renown Institute for Cancer at Renown Regional Medical Center
    • New Hampshire
      • Keene, New Hampshire, Stany Zjednoczone, 03431
        • Kingsbury Center for Cancer Care at Cheshire Medical Center
      • Lebanon, New Hampshire, Stany Zjednoczone, 03756-0002
        • Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Camden, New Jersey, Stany Zjednoczone, 08103
        • Cancer Institute of New Jersey at Cooper University Hospital - Camden
      • Vineland, New Jersey, Stany Zjednoczone, 08360
        • Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare
      • Voorhees, New Jersey, Stany Zjednoczone, 08043
        • Cancer Institute of New Jersey at Cooper - Voorhees
    • New York
      • Binghamton, New York, Stany Zjednoczone, 13905
        • Lourdes Regional Cancer Center
      • Brooklyn, New York, Stany Zjednoczone, 11209
        • Veterans Affairs Medical Center - Brooklyn
      • Buffalo, New York, Stany Zjednoczone, 14263-0001
        • Roswell Park Cancer Institute
      • East Syracuse, New York, Stany Zjednoczone, 13057
        • CCOP - Hematology-Oncology Associates of Central New York
    • North Carolina
      • Asheville, North Carolina, Stany Zjednoczone, 28801
        • Mission Hospitals - Memorial Campus
      • Goldsboro, North Carolina, Stany Zjednoczone, 27534
        • Wayne Radiation Oncology
      • Raleigh, North Carolina, Stany Zjednoczone, 27607
        • Cancer Centers of North Carolina - Raleigh
      • Wilson, North Carolina, Stany Zjednoczone, 27893
        • Wilmed Radiation Oncology Services
    • Ohio
      • Akron, Ohio, Stany Zjednoczone, 44307
        • McDowell Cancer Center at Akron General Medical Center
      • Akron, Ohio, Stany Zjednoczone, 44309-2090
        • Summa Center for Cancer Care at Akron City Hospital
      • Cincinnati, Ohio, Stany Zjednoczone, 45267
        • Charles M. Barrett Cancer Center at University Hospital
      • Salem, Ohio, Stany Zjednoczone, 44460
        • Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford
      • West Chester, Ohio, Stany Zjednoczone, 45069
        • Precision Radiotherapy at University Pointe
      • Wooster, Ohio, Stany Zjednoczone, 44691
        • Cancer Treatment Center
    • Pennsylvania
      • Abington, Pennsylvania, Stany Zjednoczone, 19001
        • Rosenfeld Cancer Center at Abington Memorial Hospital
      • Bryn Mawr, Pennsylvania, Stany Zjednoczone, 19010
        • Bryn Mawr Hospital
      • Gettysburg, Pennsylvania, Stany Zjednoczone, 17325
        • Adams Cancer Center
      • Paoli, Pennsylvania, Stany Zjednoczone, 19301-1792
        • Cancer Center of Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19111-2497
        • Fox Chase Cancer Center - Philadelphia
      • Wynnewood, Pennsylvania, Stany Zjednoczone, 19096
        • Lankenau Cancer Center at Lankenau Hospital
      • York, Pennsylvania, Stany Zjednoczone, 17405
        • York Cancer Center at Apple Hill Medical Center
    • Tennessee
      • Kingsport, Tennessee, Stany Zjednoczone, 37662
        • Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
    • Utah
      • Murray, Utah, Stany Zjednoczone, 84157
        • Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
      • Ogden, Utah, Stany Zjednoczone, 84403
        • Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
      • Provo, Utah, Stany Zjednoczone, 84604
        • Utah Valley Regional Medical Center - Provo
      • Saint George, Utah, Stany Zjednoczone, 84770
        • Dixie Regional Medical Center - East Campus
      • Salt Lake City, Utah, Stany Zjednoczone, 84143
        • LDS Hospital
    • Vermont
      • Saint Johnsbury, Vermont, Stany Zjednoczone, 05819
        • Norris Cotton Cancer Center - North
    • Virginia
      • Norfolk, Virginia, Stany Zjednoczone, 23507
        • Sentara Cancer Institute at Sentara Norfolk General Hospital
      • Portsmouth, Virginia, Stany Zjednoczone, 23708-2197
        • Naval Medical Center - Portsmouth
    • Washington
      • Yakima, Washington, Stany Zjednoczone, 98902
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
    • Wisconsin
      • Appleton, Wisconsin, Stany Zjednoczone, 54911
        • Theda Care Cancer Institute
      • Green Bay, Wisconsin, Stany Zjednoczone, 54307-3508
        • St. Vincent Hospital Regional Cancer Center
      • Marinette, Wisconsin, Stany Zjednoczone, 54143
        • Bay Area Cancer Care Center at Bay Area Medical Center
      • Menomonee Falls, Wisconsin, Stany Zjednoczone, 53051
        • Community Memorial Hospital Cancer Care Center
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
        • Medical College of Wisconsin Cancer Center
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53295
        • Veterans Affairs Medical Center - Milwaukee
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53215
        • Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
      • West Allis, Wisconsin, Stany Zjednoczone, 53227
        • West Allis Memorial Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Męski

Opis

Eligibility criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of the prostate within 12 months of registration;

  • Any one of the following clinical stages:

    • T3 disease, any N stage, M0 with any Gleason score and any prostate-specific antigen (PSA); < T3 stage, any N stage, M0 with Gleason's score ≥ 8 and any PSA; < T3 stage, any N stage, M0 with Gleason's score 7 and PSA ≥ 15 nanograms/ml; < T3 stage, any N stage, M0 with Gleason score < 7 and PSA ≥ 20 nanograms/ml.
  • A negative bone scan for metastatic disease;
  • It is mandatory that the treating physician determine the planned duration of LHRH therapy prior to the site registering the patient (minimum 1 year of therapy); If patient is receiving pre-treatment LHRH therapy, it must have begun ≤ 6 months prior to registration. If pelvic radiation therapy (RT) has started, it must have begun ≤ 8 weeks prior to registration;
  • Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup to be done within 16 weeks prior to registration:
  • History/physical examination;
  • Dental evaluation, including history of dental surgery (e.g., extraction or implant);
  • Bone scan;
  • T and L spine films;
  • DXA scan: To be eligible the patient must have a scan on Lunar, Hologic, or Norland equipment only and the T scores in both the L spine and total hip must be > negative 2.5;
  • Zubrod Performance Status 0-1 within 16 weeks prior to registration; (8/16/07)
  • Age ≥ 18;
  • Serum creatinine within 4 weeks prior to registration (8/16/07)
  • Corrected serum calcium ≥ 8.4 and ≤ 10.6 mg/dl within 8 weeks prior to registration; note: for patients with an albumin of 4.0, corrected calcium=measured calcium. The formula for corrected calcium if serum albumin value is above or below 4.0 is as follows: Corrected calcium (mg/dl) = (4 - [patient's albumin (g/dl)] x 0.8) + patient's measured calcium (mg/dl)
  • Patients who are sexually active must be willing/able to use medically acceptable forms of contraception, as the treatment involved in this study may be significantly teratogenic.
  • Patient agrees to refrain from using all products listed in Section 9.2, "Non-permitted Supportive Therapy";
  • Post-prostatectomy patients are eligible.
  • Patient must sign study specific informed consent prior to study entry.

Ineligibility criteria:

  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; e.g., carcinoma in situ of the breast or oral cavity are permissible;
  • Patients with baseline T scores of ≤ -2.5 are excluded.
  • Patients with baseline calculated creatinine clearance < 30 mL/min (estimated by Cockcroft-Gault formula below) are excluded. creatinine clearance male = [(140 - age) x (wt in kg)] / [(serum creatinine) x (72)]
  • Prior bisphosphonate therapy;
  • Prior pelvic radiation (other than for current prostate cancer) or prior systemic radiotherapeutic agents, such as strontium or samarium;
  • Patients receiving systemic chemotherapy, steroids, growth hormones, or calcitonin;
  • Patients with a history of Paget's disease or with uncontrolled thyroid or parathyroid dysfunction or with other diseases that influence bone metabolism;
  • Known hypersensitivity to zoledronic acid or other bisphosphonates;
  • Active dental problems at study entry, including infection of the teeth or jawbone; dental or fixture trauma; or a current or prior diagnosis of osteonecrosis of the jaw, exposed bone in the mouth, or slow healing after dental procedures;
  • Recent or planned

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie podtrzymujące
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Zoledronic Acid
Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
Suplement diety: Calcium
A single dose of 500 mg of elemental calcium orally each day for 3 years.
Suplement diety: Zoledronic acid
Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
Inne nazwy:
  • Zometa
  • zoledronian
Promieniowanie: radiation therapy
Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
Lek: LHRH
LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
Suplement diety: Vitamin D
400 IU (10μg), orally each day for 3 years.
Aktywny komparator: Control
Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
Suplement diety: Calcium
A single dose of 500 mg of elemental calcium orally each day for 3 years.
Promieniowanie: radiation therapy
Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
Lek: LHRH
LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
Suplement diety: Vitamin D
400 IU (10μg), orally each day for 3 years.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Freedom From Any Bone Fracture (FABF) Rate at Three Years
Ramy czasowe: From randomization to 3 years
The time of failure was measured from the date of randomization to the date of documented bone fractures, defined as any fracture of the bone. The three-year FABF rate will be estimated by the Kaplan-Meier method.
From randomization to 3 years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percent Change in Bone Mineral Density at 3 Years
Ramy czasowe: Baseline, 3 years from start of treatment
Bone mineral density (BMD) was measured by DXA scan (Dual X-ray absorptiometry) for five locations: lumbar, right total hip, left total hip, right femoral neck, and left femoral neck. The percent change at 3 years was calculated for each location by the following formula: Percent Change BMD = (BMD_3 years - BMD_Baseline)/ BMD_Baseline * 100.
Baseline, 3 years from start of treatment
Changes in the Functional Assessment of Cancer Therapy-General (FACT-G) at 3 Years
Ramy czasowe: Baseline, 3 years from start of treatment
The FACT-G is a validated, 27-item measure. In addition to a total QOL score, subscale scores for physical, functional, social and emotional well-being are produced. There are 5 responses options, with 0=Not a lot and 4=Very much. All items in a subscale are added together, multiplied by the number of items in the subscale, then divided by the number of items answered to obtain subscale totals. Scores range from 0-108 for the FACT-G total score, 0-28 for the physical, social and functional subscales, and 0-24 for the emotional subscale. Certain items, identified on the FACT-G scoring guides, must be reversed before it is added by subtracting the response from 4. All subscale totals are added together to form the FACT-G total score. Each subscale requires at least 50% of the items to be completed while the overall response rate must be greater than 80%. If items are missing, the subscale scores can be prorated. A higher score indicates better QOL.
Baseline, 3 years from start of treatment
Utility of the Use of Bisphosphonates as Assessed by Quality-adjusted Survival
Ramy czasowe: From pre-treatment to 3 years from start of treatment
The EQ-5D is a standardized instrument for measuring generic health status used to generate health utilities, used to derive quality adjusted survival. Quality adjusted survival is computed using the weighted sum of times in different health states added up to a total quality-adjusted survival time. The log-rank test is used to compare quality-adjusted survivals between the treatment arms.
From pre-treatment to 3 years from start of treatment

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Radiation Therapy Oncology Group

Współpracownicy

National Cancer Institute (NCI)

Śledczy

  • Główny śledczy: Colleen A. Lawton, MD, Medical College of Wisconsin
  • Krzesło do nauki: Matthew R. Smith, MD, Massachusetts General Hospital
  • Krzesło do nauki: Margaret Chamberlain-Wilmoth, PhD, MSS, RN, Carolinas Medical Center - University

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 marca 2006

Zakończenie podstawowe (Rzeczywisty)

1 listopada 2014

Ukończenie studiów (Rzeczywisty)

1 listopada 2014

Daty rejestracji na studia

Pierwszy przesłany

23 maja 2006

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 maja 2006

Pierwszy wysłany (Oszacować)

25 maja 2006

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

29 listopada 2017

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

23 października 2017

Ostatnia weryfikacja

1 października 2017

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • RTOG 0518
  • CDR0000476469
  • NCI-2009-00884 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Rak prostaty

Badania kliniczne na Calcium

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Canada

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj